Commitment To Patients And Their Families To Develop Therapies In

Critical Care Medicine

Conducting Bio-medical Research To Discover And Develop Novel Therapies

Introduction

Pharmazz Inc., a Delaware Corporation founded in 2010, is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It has subsidiaries Pharmazz India Private Limited, Pharmazz UK Limited and Pharmazz Europe Limited.

Company has two novel lead first-in-class drug products/candidates across multiple critical care indications.

Centhaquine: resuscitative agent free of arterial constriction

- Phase III ready in U.S. for hypovolemic shock
- Approved in India for hypovolemic shock
- Partnered with a top Indian pharmaceutical company for Southeast Asia.

Sovateltide: neuroprotective, neuroregenerative endothelin-B agonist

- Strong Phase II data published on cerebral ischemic stroke
- Phase III data in India is expected in the 2Q2022
- U.S. IND submission for Phase II trial planned for 1Q2022
- Promising preclinical results recently published in hypoxic-ischemic encephalopathy
- Potential for Rare Pediatric Disease Priority Review Voucher.

Pharmazz has a world-class management and development team with decades of successful drug development experience in the U.S. and India

Board of Directors

Anil Gulati
Director, Chairman & CEO
Dr. Gulati is leading clinical development and the commercialization of first-in-class drug products in critical care medicine. He led the discovery, development and launch of Lyfaquin for hypovolemic shock. He has 54 issued patents. He is Professor Emeritus at Midwestern University and is recipient of Paul R Dawson Biotechnology Award 2014 and Littlejohn Award 2014. Dr. Gulati is a United States Fulbright Scholar 2008-2009 and winner of International Ranbaxy Research Award 2007. Dr. Gulati was the Scientific Reviewer, United States Defense Medical Research and Development Program, Combat Casualty Care Research Program 2016 and 2017.

Neil Marwah
Director
Dr. Neil Marwah is a seasoned, entrepreneurial healthcare executive with more than 30 years of experience. His experience includes private practice, ancillary healthcare services, large provider organizations, government relations, healthcare public policy advocacy, managed care, private equity, and senior management at Global 500 enterprise. As a board-certified nephrologist, Dr. Neil Marwah has strong clinical credentials. He served on the Medical Advisory Board of Banner Health, Arizona's largest health system; and Fresenius Medical Care, a publicly traded firm with 120,000 employees.

James Ford McDonnell
Director
Dr. McDonnell received his undergraduate degree from Georgetown University and his MD in 1985 from Northwestern University Medical School. Dr. McDonnell has also received postgraduate training in Emergency and Internal Medicine at Northwestern University. He is currently Professor, Vice Chair, Director of Pediatric Ophthalmology, Retinopathy of Prematurity of Neonatal Intensive Care at the Department of Ophthalmology, Loyola University. Dr. McDonnell is the Past President of the Chicago Ophthalmological Society, and currently serves on the board of directors of the Illinois Association of Eye Physicians and Surgeons (ISEPS).

Sunil Gulati
Director, India
Mr. Gulati has more than 35 years of experience in running operations of various companies. He has considerable experience and knowledge in launching companies, getting required regulatory approvals and making the companies fully operational . along with that, he also has extensive experience in international trade.

Lov Verma
IAS (Retd.) – Director, India
Formerly, union health secretary, government of India. Mr. Verma is a very senior administrator with deep experience in the health sector. He was instrumental in formulating and implementing many policies related to the drug development process in India. He also has remarkable interest in literary work.

Manish Lavhale
Director, India
Dr. Lavhale has more than twenty years of experience in the development of novel drugs. He is PhD with 4 years of experience as a Post-Doctoral Fellow at the Midwestern University, USA. He has played a key role in filing several Investigational New Drug Applications in the USA and India.

Management

Anil Gulati
Director, Chairman & CEO
Dr. Gulati is leading clinical development and the commercialization of first-in-class drug products in critical care medicine. He led the discovery, development and launch of Lyfaquin for hypovolemic shock. He has 54 issued patents. He is Professor Emeritus at Midwestern University and is recipient of Paul R Dawson Biotechnology Award 2014 and Littlejohn Award 2014. Dr. Gulati is a United States Fulbright Scholar 2008-2009 and winner of International Ranbaxy Research Award 2007. Dr. Gulati was the Scientific Reviewer, United States Defense Medical Research and Development Program, Combat Casualty Care Research Program 2016 and 2017.

Daniel Stauder
Chief Investment Officer
Mr. Stauder has more than 35 years of experience in the healthcare capital markets and investment banking industry. He has assisted biotechnology and life science companies in raising more than $20 billion in over 500 transaction during that time. He most recently was Co-Head of Healthcare Investment Banking and Head of Healthcare Capital Markets for JMP Securities over his 10-year career at JMP. (He also held Managing Director and Director positions in Healthcare Equity Capital Markets roles at Vector Securities, Prudential Securities, RW Baird & Co., and EHS Securities.) He received his MBA from The Wharton School at the University of Pennsylvania and a BBA from the University of Notre Dame.

David Costello
Controller and Vice President
Mr. Costello brings about 20 years of accounting, budgeting, audit preparation, reporting and financial modeling experience to Pharmazz. He served as Controller for Julian Toft and Downey, Inc. and as Vice President in Transwestern Commercial Real Estate's Capital Markets Group. Mr. Costello has assisted in the closing of over $500 million in structured finance and equity transactions. Mr. Costello has a CPA designation, earning the Elijah Watts Sells Award for passing with honors, and graduated from Western Illinois University in finance, Magna Cum Laude

Sunil Gulati
Chief Operating Officer
Mr. Gulati has more than 35 years of experience in running operations of various companies. He has considerable experience and knowledge in launching companies, getting required regulatory approvals and making the companies fully operational . along with that, he also has extensive experience in international trade.

Manish Lavhale Managing Director, India
Dr. Lavhale has more than twenty years of experience in the development of novel drugs. He is PhD with 4 years of experience as a Post-Doctoral Fellow at the Midwestern University, USA. He has played a key role in filing several Investigational New Drug Applications in the USA and India.

Achievements in the past 12 months

Regulatory Milestones

1. IND approval from U.S. FDA to initiate centhaquine phase III study in hypovolemic shock
2. Agreement with Indian FDA to increase sample size for the sovateltide Phase III stroke study
3. Successful pre-IND meeting with the U.S. FDA for hypoxic-ischemic encephalopathy

Licensing Milestones

1. Entered into a licensing and marketing agreement with a major pharmaceutical company for sales in India
2. Late-stage discussion with multinational companies for marketing in U.S. and ROW

Clinical Development Milestones

1. Initiation of centhaquine septic shock investigator initiated study
2. Completion of original enrollment in sovateltide stroke phase III study
3. Completion of enrollment in Alzheimer's disease Phase II study

Product Pipeline

	Indication	Pre-clinical	Phase I	Phase II	Phase III	Market
Centhaquine (Lyfaquin®)	Hypovolemic shock					
	Septic shock					
Sovateltide	Cerebral ischemic stroke					
	Alzheimer's disease					
	Cerebral Asphyxia (HIE)					
PMZ-2123	Diabetic ketoacidosis					



Timeline of Upcoming Milestones

Milestone (United States)	Period
Centhaquine Phase III Trial Initiated for Hypovolemic Shock	1Q 2022
Centhaquine Phase III Interim Data Look	1Q 2023
Centhaquine Phase III Final Data Announced	1Q 2024
Centhaquine NDA Filed for Marketing	2Q 2024
Sovateltide Phase II IND Filed with the U.S. FDA for Cerebral Ischemic Stroke	1Q 2022
Sovateltide Phase I/II IND Filed with the U.S. FDA for Hypoxic-Ischemic Encephalopathy	2Q 2022

Milestone (India)	Period
Manufacturing of centhaquine in a US FDA approved facility	2Q 2022
Licensing and Marketing Agreement for South Asian Markets	2Q 2022
IND Filed for Hypoxic-Ischemic Encephalopathy	1Q 2022
Completion of Sovateltide Phase III Trial Cerebral Ischemic Stroke	2Q 2022
Sovateltide marketing application filed for Cerebral Ischemic Stroke	3Q 2022
Sovateltide Phase II Alzheimer's disease Data	2Q 2022

Milestones dependent upon availability of funds.

Pharmazz Inc.
+1 (630) 780-6087
50 West 75th Street, Suite 105
Willowbrook IL 60527, USA

www.pharmazz.com
info@pharmazz.com

Pharmazz India Pvt. Ltd.
+91 (120) 256-9779
H-6, Site-C, Surajpur, Industrial Area
Greater Noida (UP) – 201307, India